Alaunos Therapeutics Statistics
Alaunos Therapeutics (WEK0) Stock Statistics & Valuation Metrics
Total Valuation
Alaunos Therapeutics has a market cap or net worth of EUR 6.36M. The enterprise value is EUR 3.47M.
- Market Cap
- EUR 6.36M
- Enterprise Value
- EUR 3.47M
Share Statistics
Alaunos Therapeutics has 4,128,459 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,128,459
- Owned by Insiders
- 7.81%
- Owned by Institutions
- 1.71%
Financial Efficiency
Alaunos Therapeutics’s return on equity (ROE) is -1.94 and return on invested capital (ROIC) is -196.24%.
- Return on Equity (ROE)
- -1.94
- Return on Assets (ROA)
- -1.41
- Return on Invested Capital (ROIC)
- -196.24%
- Return on Capital Employed (ROCE)
- -1.96
- Revenue Per Employee
- 5,000
- Profits Per Employee
- -4.18M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Alaunos Therapeutics is -0.83. Alaunos Therapeutics’s PEG ratio is -0.03.
- PE Ratio
- -0.83
- PS Ratio
- 1846.49
- PB Ratio
- 6.00
- Price to FCF
- -1.96
- Price to Operating Cash Flow
- -1.44
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Alaunos Therapeutics had revenue of 5,000 and earned -4.18M in profits. Earnings per share was -2.20.
- Revenue
- 5,000
- Gross Profit
- -1.36M
- Operating Income
- -4.22M
- Pretax Income
- -4.18M
- Net Income
- -4.18M
- EBITDA
- -4.17M
- Earnings Per Share (EPS)
- -2.20
Cash Flow
In the last 12 months, operating cash flow was -2.73M and capital expenditures -98,000, giving a free cash flow of -2.82M billion.
- Operating Cash Flow
- -2.73M
- Free Cash Flow
- -2.82M
- Free Cash Flow per Share
- -1.16
Dividends & Yields
Alaunos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -50.68%
- Earnings Yield
- -101.79%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.99
- 200-Day Moving Average
- 0.99
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Alaunos Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Nov 07, 2024
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Alaunos Therapeutics as a current ratio of 2.45, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.45
- Quick Ratio
- 2.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.33
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Alaunos Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Alaunos Therapeutics EV to EBITDA ratio is -1.37, with an EV/FCF ratio of -1.93.
- EV to Sales
- 1816.63
- EV to EBITDA
- -1.37
- EV to Free Cash Flow
- -1.93
- EV to Operating Cash Flow
- -2.00
Balance Sheet
Alaunos Therapeutics has EUR 124.00K in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 124.00K billion.
- Cash & Marketable Securities
- EUR 124.00K
- Total Debt
- EUR 0.00
- Net Cash
- EUR 124.00K
- Net Cash Per Share
- EUR 0.03
- Tangible Book Value Per Share
- EUR 0.27
Margins
Gross margin is -28133.33%, with operating margin of -135266.67%, and net profit margin of -133666.67%.
- Gross Margin
- -28133.33%
- Operating Margin
- -135266.67%
- Pretax Margin
- -133666.67%
- Net Profit Margin
- -133666.67%
- EBITDA Margin
- -132866.67%
- EBIT Margin
- -133666.67%
Analyst Forecast
The average price target for Alaunos Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -54.38%
- EPS Growth Forecast
- 26.28%
